Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis (NASDAQ: NUWE) announced the return of three former employees on April 16, 2026: Liby Cielo (Principal Account Manager), Meredith Stein (Senior Clinical Education Specialist), and Scott Campbell (Area Vice President, Sales). The hires aim to accelerate commercial adoption and clinical support for Aquadex therapy across hospital and outpatient settings.
The company emphasized rebuilding commercial and clinical capacity, regional growth in South Texas and the western U.S., expanded clinician education, and support for adult and pediatric fluid‑overload patients following recent reimbursement progress.
Nuwellis (Nasdaq: NUWE) has retained CORE IR for public relations, shareholder communications, and social media management, effective April 9, 2026. CORE IR will drive market awareness, convey Nuwellis' solutions and development plans, and manage digital communications to investors, partners, and key stakeholders.
The engagement aims to support Nuwellis' growth strategy and expand outreach across medical device and diagnostics markets through integrated multi-channel communications.
Nuwellis (Nasdaq: NUWE) announced creation of a dedicated South Texas commercial territory on April 7, 2026 to strengthen hospital engagement and expand access to Aquadex therapy in a region with large hospital systems and leading cardiac and critical care programs.
The focused territory is intended to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies, reinforcing Nuwellis’ commercial infrastructure and partnerships with hospitals treating complex cardiorenal patients.
Nuwellis (Nasdaq: NUWE) reports its pediatric category became the largest and fastest-growing segment in 2025, representing approximately 50% of total U.S. revenue. The pediatric footprint expanded to 47 centers, including six of the top 10 children’s hospitals, supporting repeat utilization and institutional adoption.
The company notes Aquadex is FDA-cleared for patients ≥20 kg, and management expects pediatric growth to remain a core strategic driver as clinical evidence and market access expand.
Nuwellis (Nasdaq: NUWE) completed its acquisition of Rendiatech on March 17, 2026, adding automated continuous kidney function monitoring to its fluid management platform.
The deal brings real-time renal monitoring technology to complement the Aquadex SmartFlow System and aims to support earlier AKI detection and future renal analytics development.
Nuwellis (Nasdaq: NUWE) reported Q4 2025 revenue of $2.4 million, up 4% year-over-year and 9% sequentially, driven by a 208% increase in U.S. console sales and higher ASPs. Q4 gross margin rose to 68.2% from 58.4% a year earlier.
Full year 2025 revenue was $8.3 million, down 5% versus 2024. Operating loss for Q4 was about $2.4 million; full-year net loss attributable to common shareholders was $17.5 million, which included a $6.4 million non-cash warrant valuation expense. The company closed a $5.0 million private placement in January 2026, appointed a new CFO, and executed a definitive agreement to acquire Rendiatech.
Nuwellis (Nasdaq: NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy on March 5, 2026, strengthening clinical leadership for its cardiorenal and pediatric focus.
Dr. Goldstein, a noted pediatric nephrology and critical care expert, will advise on product development, evidence generation, pediatric innovation, and educational initiatives to advance precision fluid management and AKI care.
Nuwellis (Nasdaq: NUWE) appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The hires add public company leadership, medical device commercialization experience and capital-markets expertise to support execution of the company’s strategic priorities.
Martin Emerson brings experience leading device companies through scaling and exits, including an acquisition by BTG, and prior leadership at an organization with over $500 million in annual revenue. David McDonald returns to the board with 25+ years in healthcare capital markets and a track record of raising nearly $200 million.
Nuwellis (Nasdaq: NUWE) will report Q4 and full-year 2025 financial results on March 10, 2026. A conference call and webcast are scheduled for 9:00 AM ET to discuss results and provide a business update.
According to Nuwellis, the live webcast and an audio archive will be available on the company Investors page, and dial-in details and conference ID NUWEQ4 are provided for listeners.
Nuwellis (Nasdaq: NUWE) announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz joins from NeueHealth, where she served as Vice President of Finance and led enterprise finance, treasury, and corporate development.
Her background includes roles at Boston Scientific and Big Four public accounting, bringing public-company healthcare and medical-technology finance experience to support Nuwellis’ next phase of growth.